Activity Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of heart failure (HF) in patients with chronic kidney disease (CKD), with a forward-looking perspective on how new and novel agents might affect clinical practice. The essentials of HF and CKD disease classification, clinical trial data, and current and emerging treatment strategies will be reviewed.
System requirements for this online activity are available here.
The activity is free to all users.
Target Audience
This educational activity is directed toward cardiologists, nephrologists, primary care physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other health care professionals involved in the management of edema in patients with CKD and HF.
Learning Objectives
Upon successful completion of this activity, you should be better
prepared to:
- Assess evidence regarding current and emerging therapies to manage fluid overload in patients with CKD and comorbidities
Stephen Greene, MD
Associate Professor, Division of Cardiology
Duke University School of Medicine
Co-Director, Duke Heart Failure Medication Titration Clinic
Duke Clinical Research Institute
Durham, NC
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Corcept, CSL Vifor, Cytokinetics, Idorsia, Lexicon, Lilly, Merck, Novartis, Novo Nordisk, Otsuka, PharamIN, Recordati, Roche Diagnostics, Sanofi, Sumitomo, Tricog Health; Grant/Research Funding: AstraZeneca, Boehringer Ingelheim, Novartis, Otsuka
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity
was planned in accordance with the ACCME Standards for Integrity and
Independence to ensure balance, objectivity, independence, and scientific
rigor. Faculty were instructed to use generic names when possible and to base
recommendations on the best available evidence. Proprietary product names may
be referenced in clinical discussion for educational purposes only and do not
imply endorsement.
This activity may include discussion of
investigational, unapproved, or off‑label uses of
drugs or devices. Learners are advised to consult prescribing information for
products discussed. Content is provided for educational purposes only and is
not a substitute for the independent clinical judgment of a health care
professional. Learners are encouraged to critically evaluate the information
presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools
to support educational development. All content was reviewed and approved by
qualified faculty or planners. The accredited provider retains full
responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC
designates this enduring material for a maximum of 0.50 AMA PRA Category 1
Credits™. Physicians should claim only the credit commensurate with the
extent of their participation in the activity.
Physicians Education Resource®, LLC is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This Application-based activity is approved for a maximum of 0.50 contact hours (0.50 CEU) under UAN # 0661-0000-26-025-H01-P
Eligibility for credits requires full engagement with the enduring activity, completion of the post-activity assessment questions, completion and submission of the activity evaluation, NABP e-pid # and month/date of birth within 30 days of activity completion. No partial credits are given.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from an independent educational grant from MannKind Corporation.